(Reuters) -Drugmaker AbbVie in a regulatory filing on Friday said it expects third-quarter earnings to include a $2.7 billion charge related to in-process research and development (IPR&D) expenses.
The drugmaker also forecast third-quarter adjusted earnings per share in the range of $1.74 to $1.78, according to the filing.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Sahal Muhammed)
Comments